These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2357123)

  • 41. Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project.
    Frankenfield D; Johnson CA; Wish JB; Rocco MV; Madore F; Owen WF
    Kidney Int; 2000 Feb; 57(2):578-89. PubMed ID: 10652035
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epoetin alfa--focus on the rehabilitation of dialysis patients. Case study of the anemic patient.
    Martin-Lester M
    ANNA J; 1996 Dec; 23(6):630-3. PubMed ID: 9069794
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epoetin alfa: clinical trial therapy.
    ANNA J; 1989 Aug; 16(5):344-8. PubMed ID: 2673077
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Developing an anemia management protocol. Case study of the anemic patient.
    Hossli S
    ANNA J; 1997 Dec; 24(6):678-84; quiz 685. PubMed ID: 9444110
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Case management of the anemic patient: epoetin alfa--focus on ventricular function.
    Schardin KE
    ANNA J; 1993 Feb; 20(1):96-9. PubMed ID: 8431032
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
    Pussell BA; Walker R;
    Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Supporting epoetin alfa stimulated erythropoiesis: identifying appropriate iron levels: case study of the anemic patient.
    Sasak C
    Nephrol Nurs J; 2000 Dec; 27(6):612-5. PubMed ID: 16649342
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anemia management in pediatric dialysis patients. Case study of the anemic patient.
    Currier H
    ANNA J; 1999 Jun; 26(3):349-52. PubMed ID: 10633609
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Case management of the anemic patient. Focus on blood pressure and rHuEPO therapy.
    Holechek MJ; Watson AJ
    ANNA J; 1990 Feb; 17(1):72-3. PubMed ID: 2317107
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Administering epoetin alfa. More RBCs with fewer risks.
    Biggers PB
    Nursing; 1991 Apr; 21(4):43. PubMed ID: 2020418
    [No Abstract]   [Full Text] [Related]  

  • 51. Epoetin alfa--focus on nursing case management. Case study of the anemic patient.
    White RB
    ANNA J; 1996 Jun; 23(3):326-9. PubMed ID: 8716992
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD.
    Axelsson J; Qureshi AR; Heimbürger O; Lindholm B; Stenvinkel P; Bárány P
    Am J Kidney Dis; 2005 Oct; 46(4):628-34. PubMed ID: 16183417
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tools for analyzing trends in anemia management case study of the anemic patient.
    Aiello J
    Nephrol Nurs J; 2000 Feb; 27(1):57-60. PubMed ID: 10852692
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Case management of the anemic patient. Epoetin alfa: focus on kinetic dosing.
    Keen ML
    ANNA J; 1990 Aug; 17(4):318-9. PubMed ID: 2396859
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Developing an epoetin alfa medication protocol to improve patient care and foster collaboration.
    Shanahan M; Walton S
    ANNA J; 1995 Oct; 22(5):471-6. PubMed ID: 7487190
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The use of epoetin beta in anemic predialysis patients with chronic renal failure.
    Koch KM; Koene RA; Messinger D; Quarder O; Scigalla P
    Clin Nephrol; 1995 Sep; 44(3):201-8. PubMed ID: 8556837
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Recombinant human erythropoietin--blood transfusion alternative].
    Morshakova EF
    Antibiot Khimioter; 2000; 45(12):27-9. PubMed ID: 11212490
    [No Abstract]   [Full Text] [Related]  

  • 58. Reengineering clinical operations in a medical practice to optimize the management of anemia of chronic kidney disease.
    Joy MS; Candiani C; Vaillancourt BA; Chin H; Hogan SL; Falk RJ
    Pharmacotherapy; 2007 May; 27(5):734-44. PubMed ID: 17461709
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Erythropoietin and iron use in peritoneal dialysis patients. Report from the 1997 HCFA end-stage renal disease core indicators project.
    Bailie GR; Frankenfield DL; Prowant BF; McClellan W; Rocco MV
    Am J Kidney Dis; 1999 Jun; 33(6):1187-9. PubMed ID: 10352214
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.
    Collins AJ; Monda KL; Molony JT; Li S; Gilbertson DT; Bradbury BD
    Am J Kidney Dis; 2014 Jun; 63(6):997-1006. PubMed ID: 24315770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.